# CI-8993

Source: https://onco.cc/drugs/ci-8993/  
OnCo record `ci-8993` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CI-8993 is an experimental monoclonal antibody from ImmuNext, in phase 1 trials for advanced solid tumours; its current status is not stated.

## Summary

CI-8993 (JNJ-61610588) is a monoclonal antibody (fully human IgG1 kappa) from ImmuNext, with Curis as partner and Janssen as partner. A monoclonal antibody designed to block signalling through VISTA (V-domain Ig suppressor of T cell activation). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in 2 studies linked below. Curis's phase 1 (NCT04475523) is completed; Curis deprioritised it in November 2022 and did not exercise its option; rights reverted to ImmuNext in January 2024 (Curis 10-K for 2023). Janssen's earlier phase 1 as JNJ-61610588 (NCT02671955) was terminated. No current development found. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: JNJ-61610588
- Tags: pipeline; ctgov-ingest
- Code: CI-8993
- Modality: Monoclonal antibody (fully human IgG1 kappa)
- Mechanism: A monoclonal antibody designed to block signalling through VISTA (V-domain Ig suppressor of T cell activation).

## Sources

- ImmuNext: sec.gov: https://www.sec.gov/Archives/edgar/data/1108205/000119312520002601/d863849dex991.htm
- ImmuNext: sec.gov: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000010/cris-20231231.htm
- ImmuNext: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04475523
- ClinicalTrials.gov: trials of CI-8993: https://clinicaltrials.gov/search?intr=CI-8993

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [VISTA](https://onco.cc/targets/vista/)
- companies: [Curis](https://onco.cc/companies/curis/), [ImmuNext](https://onco.cc/companies/immunext/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer](https://onco.cc/trials/nct02671955/), [Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies](https://onco.cc/trials/nct04475523/)

---
JSON: https://onco.cc/api/v1/entities/ci-8993.json